Han Shiwei, Ma Xuemei, Zhao Yanxia, Zhao Hongying, Batista Ana, Zhou Sheng, Zhou Xiaona, Yang Yao, Wang Tingting, Bi Jingtao, Xia Zheng, Bai Zhigang, Garkavtsev Igor, Zhang Zhongtao
Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA.
Oncotarget. 2016 Jul 12;7(28):44406-44416. doi: 10.18632/oncotarget.9763.
Gastric cancer is a prevalent tumor that is usually detected at an advanced metastatic stage. Currently, standard therapies are mostly ineffective. Here, we report that Glypican-3 (GPC3) is absent in invasive tumors and metastatic lymph nodes, in particular in aggressive and highly disseminated signet ring cell carcinomas. We demonstrate that loss of GPC3 correlates with poor overall survival in patients. Moreover, we show that absence of GPC3 causes up-regulation of MAPK/FoxM1 signaling and that blockade of this pathway alters cellular invasion. An inverse correlation between GPC3 and FoxM1 is also shown in patient samples. These data identify GPC3 as a potential metastasis suppressor gene and suggest its value as a prognostic marker in gastric cancer. Development of therapies targeting signaling downstream of GPC3 are warranted.
胃癌是一种常见肿瘤,通常在晚期转移阶段才被发现。目前,标准疗法大多无效。在此,我们报告,Glypican-3(GPC3)在侵袭性肿瘤和转移淋巴结中缺失,尤其是在侵袭性强且高度播散的印戒细胞癌中。我们证明,GPC3缺失与患者总体生存率低相关。此外,我们表明,GPC3缺失导致MAPK/FoxM1信号上调,阻断该信号通路会改变细胞侵袭。在患者样本中也显示出GPC3与FoxM1呈负相关。这些数据确定GPC3为潜在的转移抑制基因,并提示其作为胃癌预后标志物的价值。开发针对GPC3下游信号的疗法是必要的。